);
Contact

Tag: Innovation

Posted on
LinkedIn Post 1
October 2025

Fertiga is attending BioJapan 2025 and Japan Society of Assisted Reproduction!

We’re proud to share that Elien Van Hecke, CCO at Fertiga, will be present in Yokohama at BioJapan 2025 (October 8-10) to connect with partners, discuss the future of fertility biotech, and showcase our pioneering work in IVF innovation. Looking forward to inspiring conversations and new collaborations! ✨

Nontheless, Fertiga is honored to be present at the Japan Society of Assisted Reproduction. Elien Van Hecke will engage with the reproductive medicine community and highlight our commitment to advancing fertility biotech and IVF innovation. Looking forward to meaningful exchanges and future collaborations!🌍

Posted on
LinkedIn Post 1
July 2025

Fertiga at the 41st ESHRE Annual Meeting in Paris, France

Fertiga, in collaboration with Brussels IVF and Merck KGaA, Darmstadt, Germany, has announced ground-breaking results from the AURORA-REC study on gene expression in ICSI patients treated with r-hFSH or r-hFSH & r-hLH. During AURORA-REC study we evaluated the differences in cumulus cell gene expression between two types of ovarian stimulation and proved that gene-based algorithms can predict live birth in these patient groups:

  • the accuracy achieved for women stimulated with r-hFSH was 69%
  • the accuracy achieved for women stimulated with r-hFSH & r-hLH was 88%

Posted on
July 2025

Fertiga teams up with Fertilab Barcelona in AURORA-Donor study

Suppressing the pituitary gland is essential during ovarian stimulation. Traditionally done via daily GnRH-antagonist injections, this study compared that approach to an alternative: using oral progesterone (Medroxyprogesterone). The key takeaways from the AURORA-Donor study so far:

  1. Both protocols are equally effective in egg maturation, fertilization, blastocyst development, and genetic quality (euploidy).
  2. No significant difference in hormonal levels or stimulation duration, but the progesterone protocol is:
  • 💰 40x more cost-efficient
  • 💊 More patient-friendly (oral vs. daily injections)
  • 🧑‍⚕️ Easier for clinics to manage.

The next step? Exploring gene expression in cumulus cells to better predict outcomes like live birth – stay tuned for more from the AURORA-Donor study!

Posted on
LinkedIn Post 1
May 2025

All eyes on Fertiga in EMD Serono Corporate Accelerator!

We’re thrilled to share that Fertiga has been selected to pitch at Women’s Health Week (previously SiS) in New York 2025 as part of the EMD Serono Corporate Accelerator (ESCA)! It’s an honour to join a select group of innovators driving change in reproductive health, with the support of EMD Serono, Inc. and M Ventures.


Posted on
LinkedIn Post 1
April 2025

All eyes on Fertiga in Women’s Health during BioTrinity 2025!!

We are proud to present our innovative fertility tests at the ‘Women’s Health’ Spotlight during BioTrinity 2025 in London, UK.

BioTrinity is an event organised by OBN (UK) Ltd, that brings together the life science community, and we are proud to attend and showcase Fertiga’s innovative Aurora Test. This is a fantastic opportunity to connect, collaborate, and explore new business opportunities in the UK.

Posted on
LinkedIn Post 1
November 2024

Fertiga presenting at ESHRE SIG Embryology Workshop!

Discover cutting-edge advancements in IVF technology, including non-invasive PGT-A, automatic vitrification, and AI-driven gamete and embryo selection at the ESHRE SIG Embryology Campus Event in Manchester, UK from 14-16 November 2024.

Don’t miss Tom Adriaenssens from Fertiga leading a hands-on session on ‘Non-invasive pregnancy prediction based on cumulus cells (AURORA-Test) in routine ART: The practical application, impact and challenges’.

Posted on
LinkedIn Post 1
August 2021

In the spotlight in VUB News!

Fertiga is a spin-off company from one of the global IVF leading centers, UZ Brussel in Belgium. UZ Brussel has been pioneering IVF, with the first ICSI baby worldwide born in 1992 from the Center of Reproductive Medicine of UZ Brussels.

Fertiga is developing the Aurora test that doubles the chances of becoming pregnant after just one fertility treatment: it improves the prediction of which egg has the highest potential for pregnancy.

“One try, one child. That should always be the goal.” – Elien Van Hecke, co-founder..

Posted on
LinkedIn Post 1
August 2021

In the spotlight in BioVox!

Fertiga, a spin-off company of the Vrije Universiteit Brussel (VUB), launched an innovation last year which considerably improve the efficiency of ICSI treatments: the Aurora test. A study with 633 patients showed that the test helped to double the pregnancy success rate of the first embryo transfer from 29 to 61 percent.

“This innovation saves people much time and emotional heartbreak,” says Elien Van Hecke, co-founder and Chief Commercial Officer (CCO) of Fertiga. “In Belgium, ICSI and IVF treatments are largely refunded by the social security system, but in countries where this is not the case the test can also save people a lot of money.”.

Posted on
LinkedIn Post 1
May 2021

In the spotlight in De Tijd!

Belgium is the world leader in research into fertility problems in couples. The start-up Fertiga is the result of this. “Helping couples who want to have children, that’s what we do it for.”

💡The core message:

  • the Brussels start-up Fertiga has developed a test that doubles the chance of success from a first IVF attempt to more than 60 percent.
  • this test costs 1,000 to 1,500 euros and is already offered at UZ Brussel.
  • the roll-out in Belgium and in the rest of the world was delayed due to the pandemic.

EN
EN